{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:04:25Z","timestamp":1793826265647,"version":"4.6.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elexacaftor\/tezacaftor\/ivacaftor (ETI) has transformed clinical outcomes in people with cystic fibrosis (pwCF), but its impact on airway and systemic inflammation is less well defined. We systematically searched PubMed, Embase, and CENTRAL (January 1, 2019, to September 30, 2025) for full-text human studies of pwCF treated with ETI that reported at least 1 inflammatory biomarker before and after ETI initiation. Because of heterogeneity in study design, sample type, biomarker panels, and assays, we did not perform a meta-analysis but instead conducted a structured narrative synthesis, grouping biomarkers by compartment (systemic vs airway); when reported, we also recorded associations between biomarker changes and clinical outcomes. Thirty-two observational studies (8-272 participants) met inclusion criteria; 25 evaluated systemic and 10 airway biomarkers, with follow-up up to 30\u2009months. ETI was associated with substantial reductions in sputum neutrophil elastase, interleukin (IL)-1\u03b2 and IL-8, and in systemic C-reactive protein (CRP), other acute-phase reactants, circulating neutrophils, and selected T cell helper (Th)17-related cytokines, indicating an overall reduction in inflammatory burden, although residual inflammation relative to healthy controls was common. Th1-associated markers and immune-cell activation phenotypes showed heterogeneous changes, but Th2\/eosinophilic markers showed less consistent modulation with ETI. Just over half of studies examined biomarker-outcome relationships; in these, reductions in neutrophil-associated markers, CRP, fibrinogen, and selected cytokines were often associated with improvements in percent predicted forced expiratory volume in 1 second (ppFEV1) or other clinical measures. ETI is associated with substantial but incomplete reductions in airway and systemic inflammation in pwCF, with the most consistent effects in neutrophil and acute-phase pathways and more variable changes across other immune markers. Persistent low-grade inflammation in many cohorts suggests that adjunctive anti-inflammatory strategies may still be relevant and that further longitudinal studies are needed to link residual biomarker abnormalities with long-term clinical and structural outcomes.<\/jats:p>","DOI":"10.1093\/annalsats\/aaoag190","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:09:03Z","timestamp":1783105743000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of elexacaftor\/tezacaftor\/ivacaftor (ETI) on airway and systemic inflammation in cystic fibrosis: a systematic review"],"prefix":"10.1093","author":[{"given":"Faisal","family":"AlMunefi","sequence":"first","affiliation":[{"name":"Division of Internal Medicine Department of Medicine, University of British Columbia , Vancouver,","place":["Canada"]},{"name":"Division of Respiratory Medicine, Department of Medicine, University of British Columbia , Vancouver,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh P","family":"Dyce","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital and University of British Columbia , Vancouver,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Y","family":"Zhao","sequence":"additional","affiliation":[{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital and University of British Columbia , Vancouver,","place":["Canada"]},{"name":"Faculty of Medicine, University of British Columbia , Vancouver,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S","family":"Quon","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, University of British Columbia , Vancouver,","place":["Canada"]},{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital and University of British Columbia , Vancouver,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026080622020296300_aaoag190-B1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2026080622020296300_aaoag190-B2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1056\/NEJMc1502191","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080622020296300_aaoag190-B3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B4","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50(suppl 40)","author":"Nichols","year":"2015","journal-title":"Pediatr Pulmonol."},{"key":"2026080622020296300_aaoag190-B5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080622020296300_aaoag190-B6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026080622020296300_aaoag190-B7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080622020296300_aaoag190-B8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026080622020296300_aaoag190-B9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026080622020296300_aaoag190-B10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080622020296300_aaoag190-B11"},{"key":"2026080622020296300_aaoag190-B12"},{"key":"2026080622020296300_aaoag190-B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"Moving the dial on airway inflammation in response to Trikafta in adolescents with cystic fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080622020296300_aaoag190-B14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"2026080622020296300_aaoag190-B15","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2026080622020296300_aaoag190-B16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcf.2023.10.019","article-title":"Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis","volume":"23","author":"Maher","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1513\/AnnalsATS.202507-817OC","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Sagel","year":"2026","journal-title":"Ann Am Thorac Soc"},{"key":"2026080622020296300_aaoag190-B18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/ppul.26334","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment reduces airway inflammation in cystic fibrosis","volume":"58","author":"De Vuyst","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026080622020296300_aaoag190-B19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ppul.26898","article-title":"Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis","volume":"59","author":"Atteih","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026080622020296300_aaoag190-B20","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis","volume":"209","author":"Loske","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080622020296300_aaoag190-B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jcf.2023.05.015","article-title":"Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis","volume":"23","author":"Martin","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jcf.2024.03.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis","volume":"23","author":"Pioch","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026080622020296300_aaoag190-B24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026080622020296300_aaoag190-B25","doi-asserted-by":"publisher","first-page":"e0304555","DOI":"10.1371\/journal.pone.0304555","article-title":"Anti-inflammatory effects of elexacaftor\/ tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del","volume":"19","author":"Jarosz-Griffiths","year":"2024","journal-title":"PLoS One"},{"key":"2026080622020296300_aaoag190-B26","doi-asserted-by":"publisher","first-page":"1486784","DOI":"10.3389\/fimmu.2025.1486784","article-title":"Proteomics profiling of inflammatory responses to elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis","volume":"16","author":"Ozuna","year":"2025","journal-title":"Front Immunol"},{"key":"2026080622020296300_aaoag190-B27","doi-asserted-by":"publisher","first-page":"27571","DOI":"10.1038\/s41598-025-12333-8","article-title":"Blood platelet reduction after elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction","volume":"15","author":"Castaldo","year":"2025","journal-title":"Sci Rep"},{"key":"2026080622020296300_aaoag190-B28","doi-asserted-by":"publisher","first-page":"2500150","DOI":"10.1183\/13993003.00150-2025","article-title":"Reduction of systemic inflammation by elexacaftor\/tezacaftor\/ivacaftor correlates with lung function improvement in cystic fibrosis","volume":"66","author":"Halle","year":"2025","journal-title":"Eur Respir J"},{"key":"2026080622020296300_aaoag190-B29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/thorax-2024-222242","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on systemic inflammation in cystic fibrosis","volume":"80","author":"Maher","year":"2025","journal-title":"Thorax"},{"key":"2026080622020296300_aaoag190-B30","doi-asserted-by":"publisher","first-page":"17534666251314706","DOI":"10.1177\/17534666251314706","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study","volume":"19","author":"Pepe","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"2026080622020296300_aaoag190-B31","doi-asserted-by":"publisher","first-page":"1107437","DOI":"10.3389\/fimmu.2023.1107437","article-title":"Regulatory T cell enhancement in adults with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"14","author":"Westh\u00f6lter","year":"2023","journal-title":"Front Immunol"},{"key":"2026080622020296300_aaoag190-B32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jcf.2025.03.004","article-title":"Vitality is associated with systemic inflammation in cystic fibrosis adults on elexacaftor\/tezacaftor\/ivacaftor","volume":"24","author":"Gravelle","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B33","doi-asserted-by":"publisher","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis: a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2026080622020296300_aaoag190-B34","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.3390\/nu16193293","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"key":"2026080622020296300_aaoag190-B35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00408-025-00806-6","article-title":"The role of triple CFTR modulator therapy in reducing systemic inflammation in cystic fibrosis","volume":"203","author":"Garc\u00eda","year":"2025","journal-title":"Lung"},{"key":"2026080622020296300_aaoag190-B36","doi-asserted-by":"publisher","first-page":"17394","DOI":"10.1038\/s41598-025-02296-1","article-title":"Improvement of iron status with elexacaftor tezacaftor ivacaftor therapy is associated with the correction of systemic inflammation and improvement of lung function: a one-year prospective study","volume":"15","author":"Lobbes","year":"2025","journal-title":"Sci Rep"},{"key":"2026080622020296300_aaoag190-B37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ppul.26805","article-title":"Analysis of iron status after initiation of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"59","author":"James","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026080622020296300_aaoag190-B38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026080622020296300_aaoag190-B39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"key":"2026080622020296300_aaoag190-B40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with Cystic Fibrosis homozygous for the F508del Mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"JCM"},{"key":"2026080622020296300_aaoag190-B41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B42","doi-asserted-by":"publisher","first-page":"2202096","DOI":"10.1183\/13993003.02096-2022","article-title":"Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis","volume":"61","author":"Dhote","year":"2023","journal-title":"Eur Respir J"},{"key":"2026080622020296300_aaoag190-B43","doi-asserted-by":"publisher","first-page":"e23428","DOI":"10.1016\/j.heliyon.2023.e23428","article-title":"Plasma levels of chemokines decrease during elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"10","author":"Westh\u00f6lter","year":"2024","journal-title":"Heliyon"},{"key":"2026080622020296300_aaoag190-B44","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13223-023-00822-2","article-title":"The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis","volume":"19","author":"Mehta","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2026080622020296300_aaoag190-B45","doi-asserted-by":"publisher","first-page":"2500616","DOI":"10.1183\/13993003.00616-2025","article-title":"Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"67","author":"Nussstein","year":"2026","journal-title":"Eur Respir J"},{"key":"2026080622020296300_aaoag190-B46","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026080622020296300_aaoag190-B47","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","article-title":"A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis","volume":"9","author":"Habib","year":"2019","journal-title":"Sci Rep"},{"key":"2026080622020296300_aaoag190-B48","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"2026080622020296300_aaoag190-B49","doi-asserted-by":"publisher","first-page":"2003502","DOI":"10.1183\/13993003.03502-2020","article-title":"Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages","volume":"57","author":"Gillan","year":"2021","journal-title":"Eur Respir J"},{"key":"2026080622020296300_aaoag190-B50","doi-asserted-by":"publisher","first-page":"Cd001505","DOI":"10.1002\/14651858.CD001505.pub5","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis","volume":"9","author":"Lands","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080622020296300_aaoag190-B51","doi-asserted-by":"publisher","first-page":"Cd002203","DOI":"10.1002\/14651858.CD002203.pub5","article-title":"Macrolide antibiotics (including azithromycin) for cystic fibrosis","volume":"2","author":"Southern","year":"2024","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoag190\/68694029\/aaoag190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoag190\/68694029\/aaoag190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article-pdf\/doi\/10.1093\/annalsats\/aaoag190\/68694029\/aaoag190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T02:02:08Z","timestamp":1786068128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/advance-article\/doi\/10.1093\/annalsats\/aaoag190\/8724504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1093\/annalsats\/aaoag190","relation":{},"ISSN":["2325-6621"],"issn-type":[{"value":"2325-6621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"aaoag190"}}